ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.8191C>G (p.Gln2731Glu)

dbSNP: rs397507966
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000225930 SCV000283335 uncertain significance Hereditary breast ovarian cancer syndrome 2023-04-28 criteria provided, single submitter clinical testing Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 236914). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 2731 of the BRCA2 protein (p.Gln2731Glu).
Mendelics RCV000225930 SCV000838869 uncertain significance Hereditary breast ovarian cancer syndrome 2018-07-02 criteria provided, single submitter clinical testing
Ambry Genetics RCV002429088 SCV002679661 uncertain significance Hereditary cancer-predisposing syndrome 2022-03-17 criteria provided, single submitter clinical testing The p.Q2731E variant (also known as c.8191C>G), located in coding exon 17 of the BRCA2 gene, results from a C to G substitution at nucleotide position 8191. The glutamine at codon 2731 is replaced by glutamic acid, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. RCV000225930 SCV004227994 uncertain significance Hereditary breast ovarian cancer syndrome 2023-10-31 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.